产品
编 号：F757307
分子式：C18H26O5
分子量：322.4
纯 度：≥95%
分子式：C18H26O5
分子量：322.4
纯 度：≥95%
产品类型
规格
价格
是否有货
5mg
2600
In-stock
25mg
8125
In-stock
结构图
CAS No: 3118-34-1
产品详情
生物活性：
Hyp9 is a transient receptor potential canonical 6 (TRPC6)-specific agonist. Hyp9 can be used for the research of spinal cord injury (SCI).
体内研究：
HP9（鞘内注射；5 μg；1、3、5 和 7 天）通过抑制 SCl 大鼠体内模型中的 AQP4 来抑制星形胶质细胞的活化和增殖，并在 SCI 后保持神经元存活和功能恢复。Animal Model:Sprague-Dawley Rats (180-220 g; adult female)
Dosage:5 μg
Administration:Intrathecally; 1, 3, 5, and 7 days
Result:Inhibited activation and proliferation of astrocytes in a rat SCI model.Reduced apoptosis and promotes neuronal survival in SCI rats by TRPC6/AQP4 signaling pathway.Facilitated functional motor recovery via TRPC6/AQP4 signaling pathway in SCI rats.
体外研究：
HYP9 (0, 1, 5, 10, 15, 20, 25, 30 μM; 72 h) 以剂量依赖性方式抑制星形胶质细胞增殖。HYP9 显著抑制 AP4 过表达。
Hyp9 is a transient receptor potential canonical 6 (TRPC6)-specific agonist. Hyp9 can be used for the research of spinal cord injury (SCI).
体内研究：
HP9（鞘内注射；5 μg；1、3、5 和 7 天）通过抑制 SCl 大鼠体内模型中的 AQP4 来抑制星形胶质细胞的活化和增殖，并在 SCI 后保持神经元存活和功能恢复。Animal Model:Sprague-Dawley Rats (180-220 g; adult female)
Dosage:5 μg
Administration:Intrathecally; 1, 3, 5, and 7 days
Result:Inhibited activation and proliferation of astrocytes in a rat SCI model.Reduced apoptosis and promotes neuronal survival in SCI rats by TRPC6/AQP4 signaling pathway.Facilitated functional motor recovery via TRPC6/AQP4 signaling pathway in SCI rats.
体外研究：
HYP9 (0, 1, 5, 10, 15, 20, 25, 30 μM; 72 h) 以剂量依赖性方式抑制星形胶质细胞增殖。HYP9 显著抑制 AP4 过表达。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备